Latest Hotspot

Carrick Therapeutics Declares the U.S. FDA Approval the IND for CT7439, a First-In-Class Inhibitor of CDK12/13

14 September 2023
3 min read

Carrick Therapeutics, a biopharma corporation focusing on cancer treatments, made an announcement that their IND application for CT7439, a unique cyclin dependent kinase 12/13 (CDK12/13) suppressor, has been given the green light by U.S FDA. Their ambition is to embark on a Phase 1 clinical study during the initial six months of 2024, intending to include patients diagnosed with advanced solid cancers such as those found in the breast, ovaries and Ewing's Sarcoma.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

"Receiving the FDA's approval for our IND application for CT7439, which represents Carrick's second therapeutic candidate, boosts our portfolio in oncology and will aid in assessing the potential of our encouraging preclinical outcomes in patients diagnosed with solid tumors," stated Carrick Therapeutics' CEO, Tim Pearson.

The first phase of the clinical trial is based on a modular structure, commencing with a dosage elevation in the initial administration of CT7439 to patients. The primary clinical assessment will be centered on safety and pharmacokinetics, accompanied by a chance for early evidence of efficacy through a blood-based pharmacodynamic assay of the homologous recombination repair (HRR) pathway.

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

图形用户界面, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of September 13, 2023, there are 1 investigational drugs for the CDC7 and CDK12 and CDK13 target, including 4 applicable indications,2 R&D institutions involved, and as many as 29 patents.
CT7439 is an inhibitor of CDK12/13 as well as a 'glue degrader' of Cyclin-K, which is the obligate co-factor for CDK12/13, giving both first-in-class and best-in-class potential. The twin modality significantly boosts the competence of the compound, resulting in the obstruction of DNA repair at the level of transcription. CDK12/13 control gene transcription by stimulating RNA Polymerase II. It carries potential to work in sync with other DDR-targeting agents like the PARP inhibitors across numerous forms of cancer like breast, ovarian and Ewing’s Sarcoma.

Opus Genetics reports the administration of their gene therapy OPGx-LCA5 to the first participant of their phase 1/2 clinical trial
Latest Hotspot
3 min read
Opus Genetics reports the administration of their gene therapy OPGx-LCA5 to the first participant of their phase 1/2 clinical trial
14 September 2023
Opus Genetics has administrated to the first patient in its first-in-human Phase 1/2 clinical trial for OPGx-LCA5.
Read →
Eloxx Pharmaceuticals Shares Program Report on Phase 2 Alport Trial involving ELX-02
Latest Hotspot
3 min read
Eloxx Pharmaceuticals Shares Program Report on Phase 2 Alport Trial involving ELX-02
14 September 2023
Eloxx Pharmaceuticals, Inc. provided new information on the development of ELX-02 in the context of handling Alport syndrome caused by nonsense mutations.
Read →
Wang Shaomeng's research group reports AR receptor PROTAC drug ARD-1676, with a bioavailability as high as 99%
Advanced Tech.
9 min read
Wang Shaomeng's research group reports AR receptor PROTAC drug ARD-1676, with a bioavailability as high as 99%
14 September 2023
The research group of Wang Shaomeng recently published a paper in JMC, reporting the discovery of ARD-1676 and characterizing its preclinical properties.
Read →
Janssen presents an application for Marketing Authorisation to the EMA, requesting endorsement for Erdafitinib's utilization in the management of patients
Latest Hotspot
4 min read
Janssen presents an application for Marketing Authorisation to the EMA, requesting endorsement for Erdafitinib's utilization in the management of patients
14 September 2023
Janssen Pharmaceuticals filed a Marketing Authorisation Application with EMA to get approval for Erdafitinib. The drug is for adult patients with advanced or metastatic urothelial carcinoma, showing progression after a PD-1/PD-L1 inhibitor therapy, with susceptible FGFR3 mutations.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.